Anti-Diabetes Drugs - United Arab Emirates

The Anti-Diabetes Drugs market in the United Arab Emirates is expected to witness a significant growth in revenue, reaching a projected value of US$146.00m in 2024.
This market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 8.43%, ultimately leading to a market volume of US$218.90m by 2029.
When compared globally, it is noteworthy that United States will generate the highest revenue in this market, amounting to US$37.84bn in 2024.
The United Arab Emirates is witnessing an increase in demand for innovative anti-diabetes drugs due to a rising prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in United Arab Emirates has been steadily growing over the past few years.

Customer preferences: The demand for Anti-Diabetes Drugs in United Arab Emirates is mainly driven by the increasing prevalence of diabetes in the country. According to the International Diabetes Federation, the prevalence of diabetes in United Arab Emirates is one of the highest in the world. The population in United Arab Emirates is also becoming more health-conscious and aware of the importance of managing diabetes, which is further driving the demand for Anti-Diabetes Drugs.

Trends in the market: The Anti-Diabetes Drugs market in United Arab Emirates is witnessing a shift towards more innovative and advanced drugs. The market is dominated by multinational pharmaceutical companies, who are investing heavily in research and development to bring new and improved products to the market. There is also a growing trend towards combination therapies, which offer better efficacy and convenience for patients.

Local special circumstances: The healthcare system in United Arab Emirates is largely government-funded, which means that the government plays a significant role in regulating the pharmaceutical industry. The government has implemented various initiatives to improve the quality of healthcare in the country, including the National Diabetes Strategy, which aims to reduce the incidence of diabetes and improve the management of the disease.

Underlying macroeconomic factors: The economy of United Arab Emirates is largely driven by the oil and gas industry, which has been affected by the global economic downturn. However, the government has been investing heavily in diversifying the economy, particularly in the healthcare sector. This has led to an increase in healthcare spending and a growing demand for Anti-Diabetes Drugs. The government has also been promoting medical tourism, which is expected to further boost the demand for Anti-Diabetes Drugs in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.